Section Arrow
DRMA.NASDAQ
- Dermata Therapeutics
  suspend
(Financial Status)
Quotes are at least 15-min delayed:2024/05/16 03:04 EDT
Last
 0.33
-0.0056 (-1.67%)
Day High 
0.3399 
Prev. Close
0.3356 
1-M High
0.4114 
Volume 
125.31K 
Bid
--
Ask
--
Day Low
0.32 
Open
0.3375 
1-M Low
0.232 
Market Cap 
2.24M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.34 
20-SMA 0.34 
50-SMA 0.38 
52-W High 2.8101 
52-W Low 0.232 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.67/-0.82
Enterprise Value
2.24M
Balance Sheet
Book Value Per Share
0.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 03:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Itstwo product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.